Optimal Medication Management for Patients with Atrial Fibrillation and Recent Cardiac Surgery

Anticoagulation Management

The European Society of Cardiology recommends transitioning from triple therapy to dual therapy (oral anticoagulant plus single antiplatelet) after 1-6 months depending on stent type and bleeding risk for patients with recent triple bypass and atrial fibrillation 1
Triple therapy should be limited to the minimum duration necessary, typically 1 month for bare-metal stents or 3-6 months for drug-eluting stents, according to the European Heart Journal 1
The patient should be transitioned to an oral anticoagulant plus clopidogrel 75 mg daily (or alternatively, aspirin 100 mg daily) for up to 12 months, as recommended by the European Heart Journal 1
Long-term therapy should be oral anticoagulation alone after 12 months, as suggested by the European Heart Journal 1
Pantoprazole 40 mg should be continued for gastric protection due to Barrett's esophagus and as prophylaxis while on antithrombotic therapy, according to the European Heart Journal 1

For patients with atrial fibrillation and preserved ejection fraction, the American College of Cardiology recommends a beta-blocker (metoprolol) or non-dihydropyridine calcium channel antagonist as first-line therapy for rate control 4, 5
The combination of digoxin and a beta-blocker is reasonable to control heart rate both at rest and during exercise, as stated by the American College of Cardiology 3
Amiodarone for rate control should be considered only when other measures are unsuccessful or contraindicated, according to the American College of Cardiology and the Circulation journal 3, 5

Amiodarone has significant potential for drug interactions with digoxin (increases digoxin levels, increasing risk of toxicity) and warfarin (if used instead of rivaroxaban), as reported by the American College of Cardiology 6

The European Heart Journal recommends continuing rivaroxaban but considering dose adjustment based on renal function and bleeding risk 1
The European Heart Journal suggests transitioning from triple therapy to dual therapy (rivaroxaban + single antiplatelet) at the appropriate time based on stent type 1
The European Heart Journal recommends planning for eventual transition to anticoagulant monotherapy after 12 months 1
The American College of Cardiology recommends continuing metoprolol as primary rate control agent 4, 5
The American College of Cardiology suggests reassessing the need for digoxin and continuing if needed for adequate rate control 3
The American College of Cardiology and the Circulation journal recommend considering discontinuing amiodarone if used solely for rate control and not rhythm control 3, 5